Menopausal hormone therapy and cancer risks of reproductive system. Literature review

2019 ◽  
Vol 1 (1) ◽  
pp. 42-50
Author(s):  
Ya. Z. Zaydieva
Keyword(s):  
Literature Review ◽  
Hormone Therapy ◽  
Hormonal Therapy ◽  
Reproductive System ◽  
Menopausal Hormone Therapy ◽  
Menopausal Transition ◽  
Continuous Mode ◽  
Cancer Risks ◽  
Oncological Diseases

Data on risks of development of oncological diseases of bodies of reproductive system in women during menopausal transition and in a postmenopause are submitted at treatment of menopausal frustration by the preparations intended for menopausal hormonal therapy, the containing various doses of estrogen and progestogen used in the cyclic or continuous mode.

Menopausal transition: risks and their prevention

2020 ◽  
pp. 26-30
Author(s):  
L. V. Tkachenko ◽  
N. I. Sviridova
Keyword(s):  
Hormone Therapy ◽  
Sex Hormones ◽  
Crucial Role ◽  
Dosage Forms ◽  
Estrogen Deficiency ◽  
Menopausal Hormone Therapy ◽  
Menopausal Transition ◽  
Cancer Risks ◽  
Compensatory Reactions ◽  
Urogenital Symptoms

The period of the menopausal transition from 40–45 years to menopause – is the crucial period of a woman’s life, in which, against the background of increasing estrogen deficiency, in addition to the appearance of vasomotor, psychological, and urogenital symptoms, complications and exacerbations of accumulated extagenital diseases occur. The loss of the natural balance of sex hormones leads to hyperplastic processes in hormone-dependent tissues, which leads to cancer risks. In solving this problem, menopausal hormone therapy (MHT) can play a crucial role, but this will become possible if, when choosing drugs for MHT, preference will be given to the safest dosage forms that provide the whole spectrum of compensatory reactions, including the prevention of dramatic situations of this age.

scholarly journals Risk of venous thromboembolism in users of contraception and menopausal hormone therapy during the COVID-19 pandemic

2020 ◽  
Vol 66 (suppl 2) ◽  
pp. 22-26
Author(s):  
Andréa Larissa Ribeiro Pires ◽  
José Gomes Batista ◽  
José Mendes Aldrighi ◽  
Irineu Francisco Delfino Silva Massaia ◽  
Diego Medeiros Delgado ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Hormone Therapy ◽  
Hormonal Therapy ◽  
Management Strategies ◽  
Hormonal Contraception ◽  
Menopausal Hormone Therapy ◽  
Safety Measures ◽  
Thromboembolic Risk ◽  
Combined Hormonal Contraception ◽  
Inflammatory Changes

SUMMARY OBJECTIVES The outbreak of coronavirus disease (COVID-19) is a public health emergency of international concern. Inflammatory changes are part of COVID-19 pathophysiology and this might generate a higher thromboembolic risk in patients using combined hormonal contraception and menopausal hormone therapy. We aimed to discuss the main aspects related to this issue and propose management strategies for women affected by COVID-19. METHODS This narrative review collected information from several articles published since the beginning of the outbreak of the new coronavirus disease about the pathophysiology, stage of the disease, the occurrence of thrombotic events, and the risk of thromboembolism in users of contraception and hormonal therapy. RESULTS This article consolidates clinical parameters about the risk of venous thromboembolism in users of contraception and menopausal hormone therapy emphasizing the probable increase of that risk in women with suspected or confirmed COVID-19 and bringing safer recommendations. CONCLUSIONS In this scenario, apart from the fundamental orientations of preventive measures, like social isolation and hygiene, it is important that all female health professionals have knowledge of the new rules and adopt safety measures, especially on the prescription of hormonal therapy and contraception.

Management of patients with uterine bleeding during menopausal hormone therapy

2021 ◽  
Author(s):  
А.З. Хашукоева ◽  
М.В. Бурденко ◽  
А.В. Оверко ◽  
Т.Е. Рыжова ◽  
М.С. Сафонина
Keyword(s):  
Life Expectancy ◽  
Hormone Therapy ◽  
Uterine Bleeding ◽  
Menopausal Hormone Therapy ◽  
Menopausal Transition ◽  
Therapeutic Effects ◽  
Climacteric Syndrome ◽  
Climacteric Symptoms ◽  
Long Life ◽  
Selection Of

Тенденции по увеличению продолжительности жизни, которые наблюдаются в последние десятилетия, напрямую затрагивают деятельность акушера-гинеколога ввиду того, что женщинам необходимо не только прожить долгую жизнь, но и снизить количество заболеваний, развитие которых нередко связано с наступлением периода менопаузального перехода и постменопаузы. Задача врачей – помочь пациенткам максимально мягко войти в период постменопаузы, минимизировав проявления климактерического синдрома. В настоящее время наиболее эффективным методом терапии ранних климактерических симптомов является менопаузальная гормональная терапия. В статье рассмотрены современные подходы к проведению менопаузальной гормональной терапии при возникновении менопаузальных расстройств, подходы к подбору менопаузальной гормональной терапии с учетом особенностей каждой конкретной пациентки. Рассматриваются терапевтические эффекты и возможности менопаузальной гормональной терапии, проблемы ее приемлемости, а также ведение пациенток в постменопаузальном периоде с маточными кровотечениями. The trends in life expectancy that have been observed in recent decades directly affect the activities of an obstetrician-gynecologist due to the fact that women need not only to live a long life, but also to reduce the number of diseases, the development of which is often associated with the onset of the menopausal transition and postmenopause. The task of doctors is to help patients to enter the postmenopausal period as gently as possible, minimizing the manifestations of the climacteric syndrome. Currently, the most effective method of treating early climacteric symptoms is menopausal hormone therapy. The article discusses modern approaches to the conduct of menopausal hormone therapy in the event of menopausal disorders, approaches to the selection of menopausal hormone therapy, taking into account the characteristics of each individual patient. The therapeutic effects and possibilities of menopausal hormone therapy, the problems of its acceptability, as well as the management of postmenopausal patients with uterine bleeding are considered.

Clarifying breast cancer risks associated with menopausal hormone therapy

2006 ◽  
Vol 7 (11) ◽  
pp. 885-886 ◽  
Author(s):  
Montserrat Garcia-Closas ◽  
Mark E Sherman ◽  
Louise A Brinton
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Menopausal Hormone Therapy ◽  
Cancer Risks

Menopausal hormone therapy and uterine cancer: the acceptability of the tandem

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (6) ◽  
pp. 42-47
Author(s):  
O V Yakushevskaya ◽  
S V Yureneva ◽  
A E Protasova ◽  
G N Khabas ◽  
M R Dumanovskaya
Keyword(s):  
Hormone Therapy ◽  
Uterine Cancer ◽  
Menopausal Hormone Therapy ◽  
Medical Rehabilitation ◽  
Cytostatic Treatment ◽  
Systematic Analysis ◽  
Strict Adherence ◽  
Patient Profile ◽  
The Past

The aim of the work is to conduct a systematic analysis of the available research results on the possibility of using menopausal hormone therapy (MHT) in patients who successfully completed the treatment of endometrial cancer (EC). Materials and methods. The review includes data from foreign articles published in PubMed and Medline, and domestic works published on elibrary.ru over the past 40 years. Results. The results obtained allow us to consider MHT as an independent method of medical rehabilitation for women who have undergone EC. A clear patient profile should be established, allowing the use of this method, with strict adherence to health monitoring. Conclusion Patients who have successfully completed the treatment of EC require the creation of special rehabilitation conditions in the interests of maintaining health and quality of life and should be under the close attention of the doctor. Argumented approaches to the appointment of MHT in such patients will avoid complications associated with estrogen deficiency after surgery, radiation with or without systemic (cytostatic) treatment methods.

The role of orexin A in pathophysiological mechanisms of sleep disorder in postmenopausal women

GYNECOLOGY ◽  
2020 ◽  
Vol 22 (1) ◽  
pp. 50-54
Author(s):  
Zukhra Kh. Ebzieva ◽  
Svetlana V. Yureneva ◽  
Tatiana Yu. Ivanets
Keyword(s):  
Hormone Therapy ◽  
Sleep Disorder ◽  
Postmenopausal Women ◽  
Menopausal Hormone Therapy ◽  
Reproductive Age ◽  
Vasomotor Symptoms ◽  
Women Of Reproductive Age ◽  
Orexin A ◽  
Group 1

Aim. To conduct a comparative analysis of serum orexin A levels in women of different age periods with and without sleep disorder and vasomotor symptoms. To evaluate the dynamics of orexin A levels under menopausal hormone therapy. Materials and methods. The study included 50 postmenopausal women and 30 women of reproductive age with a regular menstrual cycle. Using block randomization, patients are divided into 3 groups: group 1 (main group), n=25, -STRAW+ 10 (+1b and +1c), patients with sleep disorder and vasomotor symptoms; group 2 (comparison group), n=25, STRAW+ 10 (+1b and +1c), patients with vasomotor symptoms without sleep disorder; group 3 (control group), n=30, STRAW+ 10 (-4), women of reproductive age without sleep disorder. Group 1 patients were given menopausal hormone therapy. A comparative analysis was carried out using the questionnaire for assessing menopausal symptoms severity by the Greene Scale (the Greene Climacteric Scale) and Rating Scale for subjective sleep characteristics. After 12 weeks of treatment, a control examination was performed. Results. In group 1 women, the serum orexin A levels were significantly higher compared to the women without the symptoms. The link between the orexin A levels and menopause syndrome severity was established. A significant decrease in the menopausal symptoms severity after 12 weeks of menopausal hormone therapy was shown. It was accompanied by a 1,3-fold decrease in orexin A levels. Conclusions. The obtained data indicate the possible role of orexin A and the orexin neuropeptide system in the pathogenesis of sleep disorder and vasomotor symptoms in postmenopausal women.

Sign in / Sign up

Export Citation Format

Share Document